Breadcrumb

Raffit  Hassan, M.D.

Raffit Hassan, M.D.

  • Center for Cancer Research
  • National Cancer Institute

RESEARCH SUMMARY

Dr. Hassan has played a pivotal role in validating the tumor differentiation antigen mesothelin as a target for cancer therapy and development of mesothelin targeted immunotherapy. This work has laid the foundation for several mesothelin directed agents that he is evaluating in the clinic for treatment of mesothelioma, lung and pancreatic cancer. His clinical trials using an anti-mesothelin immunotoxin has shown major tumor responses in patients with mesothelioma. Ongoing efforts are directed to exploiting this approach for treatment of lung and pancreatic cancer.

Areas of Expertise

1) mesothelioma, 2) mesothelin, 3) immunotoxins, 4) immunotherapy, 5) lung cancer,
6) pancreatic cancer

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them. 

Publications

Selected Key Publications

Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models

Jiang Q, Ghafoor A, Mian I, Rathkey D, Thomas A, Alewine C, Sengupta M, Ahlman MA, Zhang J, Morrow B, Steinberg SM, Pastan I, Hassan R.
Sci Transl Med. 12 (550): 2020.
Full-Text Article
[ Journal Article ]

Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin

Hassan R, Alewine C, Mian I, Spreafico A, Siu LL, Gomez-Roca C, Delord JP, Italiano A, Lassen U, Soria JC, Bahleda R, Thomas A, Steinberg SM, Peer CJ, Figg WD, Niederfellner G, Méresse Naegelen V, Pastan I.
Cancer. 126 (22): 4936-4947, 2020.
Full-Text Article
[ Journal Article ]

First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors

Hassan R, Blumenschein GR Jr, Moore KN, Santin AD, Kindler HL, Nemunaitis JJ, Seward SM, Thomas A, Kim SK, Rajagopalan P, Walter AO, Laurent D, Childs BH, Sarapa N, Elbi C, Bendell JC.
J Clin Oncol. 38 (16): 1824-1835, 2020.
Full-Text Article
[ Journal Article ]

Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy

Hassan R, Morrow B, Thomas A, Walsh T, Lee MK, Gulsuner S, Gadiraju M, Panou V, Gao S, Mian I, Khan J, Raffeld M, Patel S, Xi L, Wei JS, Hesdorffer M, Zhang J, Calzone K, Desai A, Padiernos E, Alewine C, Schrump DS, Steinberg SM, Kindler HL, King MC, Churpek JE.
Proc Natl Acad Sci USA. 116 (18): 9008-9013, 2019.
Full-Text Article
[ Journal Article ]

Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients

Khanna S, Graef S, Mussai F, Thomas A, Wali N, Yenidunya BG, Yuan C, Morrow B, Zhang J, Korangy F, Greten TF, Steinberg SM, Stetler-Stevenson M, Middleton G, De Santo C, Hassan R.
Clin Cancer Res. 24 (12): 2859-2872, 2018.
Full-Text Article
[ Journal Article ]

Job Vacancies

There are no open positions at this time. Check back again later, or take a look at CCR's Careers page.

Team

Clinical Research Nurse (Contr)
Maria Garcia Agra, R.N.
Research Fellow
Romi Biswas, Ph.D.
Clinical Collaborator
Gideon Blumenthal, M.D.
Staff Scientist
Qun Jiang, Ph.D.
Postdoctoral Fellow (Visiting)
Mana Kamana Khanal, Ph.D.
Clinical Fellow
Chul Kim, M.D.
Scientist (Contr)
Firouzeh Korangy, Ph.D.
Clinical Fellow
Idrees Mian, M.D.
Bioinformatics Scientist (Contr.)
Vikram Misra, Ph.D.
Biologist
Betsy Morrow
Clinical Trials Specialist (Contr.)
Manjistha Sengupta, Ph.D.
Postdoctoral Fellow (Visiting)
Chaido Stathopoulou, Ph.D.
Postdoctoral Fellow (Visiting)
Sakshi Tomar, Ph.D.
Biologist
Jingli Zhang

Covers

Clinical Cancer Research, October 1, 2019

Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma

Published Date

The cover shows a section of a tumor biopsy from a patient with malignant mesothelioma. Multiplex immunohistochemical staining reveals different immune cell populations infiltrating the tumor. 

Citation

R. Hassan, E. Alley, H. Kindler, S. Antonia, T. Jahan, S. Honarmand, N. Nair, C. C. Whiting, A. Enstrom, E. Lemmens, T. Tsujikawa, S. Kumar, G. Choe, A. Thomas, K. McDougall, A. L. Murphy, E. Jaffee, L. M. Coussens, D. G. Brockstedt, Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma. Clin Cancer Res 25, 5787-5798 (2019).

Journal of Thoracic Oncology, March 15, 2020

Anaplastic Lymphoma Kinase Gene Rearrangement in Children and Young Adults With Mesothelioma

Published Date

Peritoneal mesothelioma with ALK-STRN fusion mapping breakpoint to exon 3 of STRN and intron 19 of ALK. The resulting fusion protein contains domains for the Striatin protein and the kinase domain for ALK.

Citation

I. Mian, Z. Abdullaev, B. Morrow, R. N. Kaplan, S. Gao, M. Miettinen, D. S. Schrump, V. Zgonc, J. S. Wei, J. Khan, S. Pack, R. Hassan, Anaplastic Lymphoma Kinase Gene Rearrangement in Children and Young Adults With Mesothelioma. J Thorac Oncol 15, 457-461 (2020).

Science Translational Medicine, July 1, 2020

Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models

Published Date

Improving Immunotherapy: A mesothelin-targeted immunotoxin enhances the anti-tumor activity of immune checkpoint inhibitor in patients with mesothelioma and in mice.

Citation

Q. Jiang, A. Ghafoor, I. Mian, D. Rathkey, A. Thomas, C. Alewine, M. Sengupta, M. A. Ahlman, J. Zhang, B. Morrow, S. M. Steinberg, I. Pastan, R. Hassan, Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models. Sci Transl Med 12, (550):eaaz7252 (2020).